Market closed
Kura Oncology/KURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Ticker
KURA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
142
Website
Kura Oncology Metrics
BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$2.24
EPS
0.84
Beta
-
Dividend rate
Price and volume
Market cap
$1.3B
Beta
0.84
52-week high
$24.17
52-week low
$7.52
Average daily volume
547K
Financial strength
Current ratio
14.94
Quick ratio
14.834
Long term debt to equity
3.094
Total debt to equity
3.59
Interest coverage (TTM)
-124.90%
Management effectiveness
Return on assets (TTM)
-24.77%
Return on equity (TTM)
-39.27%
Valuation
Price to book
2.87
Price to tangible book (TTM)
2.87
Price to free cash flow (TTM)
-9.195
Growth
Earnings per share change (TTM)
9.03%
3-year earnings per share growth (CAGR)
6.60%
What the Analysts think about Kura Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Kura Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Kura Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Kura Oncology News
AllArticlesVideos
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
GlobeNewsWire·3 days ago
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
GlobeNewsWire·4 days ago
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $1.3B as of October 26, 2024.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of October 26, 2024.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.